Virus Epstein-Barr

Advancing Early Detection of Nasopharyngeal Carcinoma: Evaluating the Novel Anti-BNLF2b Antibody Test

By MedXY 07/11/2026

This article critically appraises a multicenter study validating the Anti-BNLF2b antibody (P85-Ab) assay, highlighting its superior sensitivity and specificity for early nasopharyngeal carcinoma detection compared to established EBV-based biomarkers.

news Oncology Otorhinolaryngology

Anti-EBV BNLF2b Antibody Shows High Accuracy for Outpatient Diagnosis of Suspected Nasopharyngeal Carcinoma

By MedXY 05/25/2026

In a prospective multicenter cohort, P85-Ab achieved 93.0% sensitivity and 97.3% specificity for suspected nasopharyngeal carcinoma, outperforming conventional EBV serologies in outpatient practice.

Hematology-Oncology news Otorhinolaryngology

Diagnostic Performance of Anti-Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma

By MedXY 05/25/2026

P85-Ab, an anti-EBV BNLF2b antibody test, showed excellent accuracy for suspected nasopharyngeal carcinoma and outperformed older EBV markers in most outpatient settings.

Gastroenterology news Oncology

Gut Microbiome Signatures Improve Diagnosis and Prognostic Stratification in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

By MedXY 05/07/2026

A large shotgun metagenomic study links gut dysbiosis to EBV-associated nasopharyngeal carcinoma and shows that microbial markers, especially combined with EBV markers, may strengthen diagnosis and prognostic assessment.

Neurology news

High-Level EBNA-1 Antibodies: A Precise Biomarker for Differentiating Multiple Sclerosis From MOGAD and NMOSD

By MedXY 03/11/2026

A large-scale multicenter study reveals that persistent high-level Epstein-Barr nuclear antigen 1 (EBNA-1) peptide antibody titers serve as a highly specific biomarker, effectively distinguishing Multiple Sclerosis from other neuroinflammatory mimics like MOGAD and NMOSD, even in seronegative cases.